# Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

> **NCT00002864** · PHASE3 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 667 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** octreotide acetate
- **DRUG:** tamoxifen citrate

## Key facts

- **NCT ID:** NCT00002864
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-09-24
- **Primary completion:** 2007-12-07
- **Final completion:** 2010-04-23
- **Target enrollment:** 667 (ACTUAL)
- **Last updated:** 2020-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002864, "Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00002864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*